Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

Rountree, Susan D, Chan, Wenyaw, Pavlik, Valory N, Darby, Eveleen J, Siddiqui, Samina, Doody, Rachelle S·2009·Alzheimers Res Ther
DOI 10.1186/alzrt7

Cited by (184)

Items 101–184 of 184

  1. FDG-PET in Early AD Diagnosis
    Jessica Chew, Daniel H.S. Silverman · 2013 · Medical Clinics of North America
  2. Photobiomodulation regulates astrocyte activity and ameliorates scopolamine-induced cognitive behavioral decline
    J. Park, Namgue Hong, Min Young Lee, Jin-Chul Ahn · 2024 · Frontiers in Cellular Neuroscience
  3. Clinical Applications of PET Imaging in Alzheimer’s Disease
    Shiv Patil, Cyrus Ayubcha, Eric M. Teichner, Robert C. Subtirelu, Julia H Cho, Mohanad Ghonim, Mohamed Ghonim, Thomas J. Werner, Poul Flemming Høilund‐Carlsen, Abass Alavi et al. · 2024 · PET Clinics
  4. Pharmacological treatment for Alzheimer's disease: current approaches and future strategies.
    Ling‐Yun Fan, Ming‐Jang Chiu · 2010 · PubMed
  5. Synthesis and Initial Characterization of a Selective, Pseudo‐irreversible Inhibitor of Human Butyrylcholinesterase as PET Tracer
    Christian Gentzsch, Matthias Hoffmann, Yasuhiro Ohshima, Naoko Nose, Xinyu Chen, Takahiro Higuchi, Michael W. Decker · 2021 · ChemMedChem
  6. Memantine in Alzheimer’s disease: experience in an Alzheimer’s disease assessment unit
    Elena Sinforiani, Chiara Pasotti, Laura Chiapella, Paola Malinverni, Chiara Zucchella · 2012 · Aging Clinical and Experimental Research
  7. Combining Chalcones with Donepezil to Inhibit Both Cholinesterases and Aβ Fibril Assembly
    Nishad Thamban Chandrika, Marina Y. Fosso, Oleg V. Tsodikov, Harry LeVine, Sylvie Garneau‐Tsodikova · 2019 · Molecules
  8. Extracts of Sideritis scardica and Clinopodium vulgare Alleviate Cognitive Impairments in Scopolamine-Induced Rat Dementia
    Maria I. Lazarova, Elina R. Tsvetanova, Almira P. Georgieva, Miroslava O. Stefanova, Diamara N. Uzunova, Petko Nedyalkov Denev, Valya Vassileva, Krasimira N. Tasheva · 2024 · International Journal of Molecular Sciences
  9. POST HOC EVIDENCE FOR AN ADDITIVE EFFECT OF MEMANTINE AND DONEPEZIL: CONSISTENT FINDINGS FROM DOMINO-AD STUDY AND MEMANTINE CLINICAL TRIAL PROGRAM
    Suzanne B. Hendrix, N. Ellison, S. Stanworth, Victor Otcheretko, Pierre N. Tariot · 2015 · The Journal of Prevention of Alzheimer s Disease
  10. Eclalbasaponin II Ameliorates the Cognitive Impairment Induced by Cholinergic Blockade in Mice
    Won Yong Jung, Haneul Kim, Se Jin Jeon, Hye Jin Park, Hyuck Jai Choi, Nam Jae Kim, Dong Hyun Kim, Dae Sik Jang, Jong Hoon Ryu · 2017 · Neurochemical Research
  11. Quercetin mitigates scopolamine-induced memory dysfunction: impact on oxidative stress and cholinergic mechanisms
    Juliet N. Olayinka, Anthony Taghogho Eduviere, Olusegun Adebayo Adeoluwa, Elizabeth Toyin Akinluyi, Abiola Oluwatosin Obisesan, Oluwole B. Akawa, Adeshina Adebanjo · 2021 · Metabolic Brain Disease
  12. Could cholinesterase inhibitors be harmful over the long term?
    Lon S. Schneider · 2011 · International Psychogeriatrics
  13. Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan
    Chee‐Jen Chang, Tse‐Chih Chou, Chiung‐Chih Chang, Ta‐Fu Chen, Chaur‐Jong Hu, Jong‐Ling Fuh, Wenfu Wang, Chiung‐Mei Chen, Winco Hsu, Chin‐Chang Huang · 2018 · Alzheimer s & Dementia Translational Research & Clinical Interventions
  14. Lemon Grass Tea Enhanced Memory Function and Attenuated Scopolamine-Induced Amnesia in Mice Via Inhibition of Oxidative Stress and Acetyl-Cholinesterase Activity
    Solomon Umukoro, Adeyinka Habeeb Adeola, Benneth Ben‐Azu, Abayomi Mayowa Ajayi · 2018 · Journal of Herbs Spices & Medicinal Plants
  15. Citicoline: A Cholinergic Precursor with a Pivotal Role in Dementia and Alzheimer’s Disease
    Pietro Gareri, Antonino Maria Cotroneo, Roberta Montella, Matteo Gaglianone, Salvatore Putignano · 2024 · Journal of Alzheimer s Disease
  16. Jobelyn® extends the life span and improves motor function in Drosophila melanogaster exposed to lipopolysaccharide via augmentation of antioxidant status
    Ruth John, Amos Olalekan Abolaji, Adeola Oluwatosin Adedara, Abayomi Mayowa Ajayi, Adegbuyi Oladele Aderibigbe, Solomon Umukoro · 2022 · Metabolic Brain Disease
  17. Comparison of Malondialdehyde, Acetylcholinesterase, and Apoptosis-Related Markers in the Cortex and Hippocampus of Cognitively Dysfunctional Mice Induced by Scopolamine
    Hee‐Jung Park, Myeong-Hyun Nam, Ji-Hoon Park, Jimin Lee, Hye-Sun Hong, Taewoo Kim, In-Ho Lee, Chang-Ho Shin, Soo‐Hong Lee, Young‐Kwon Seo · 2024 · Biomedicines
  18. Development and Dissemination of an Interprofessional Online Dementia Training Curriculum
    Jennifer L. Bryan, Ali Abbas Asghar‐Ali · 2019 · Journal of the American Geriatrics Society
  19. Ginseng exhibits adaptogenic-like activity in mice exposed to hypoxic-anoxic stress through activation of antioxidant/BDNF protective mechanisms and inhibition of pro-inflammatory cytokines/NF-KB signaling pathways
    James Olukayode Oni, Divine Oluwaferanmi Oyenekan, Yetunde Olamide Olayemi, Osarugue Christabel Irabor, Precious Ogbuji, McCarthy Oritseweyinmi Tova, Paul Ademola Adeleke, Gbemisayo Adetomiwa Abbas, Solomon Umukoro · 2025 · Pharmacological Research - Modern Chinese Medicine
  20. Effect of drug compliance on health care costs in newly-diagnosed dementia: Analysis of nationwide population-based data
    Seung-Taek Oh, Kyu‐Tae Han, Won‐Jung Choi, Jaesub Park · 2019 · Journal of Psychiatric Research
  21. Transdermal rivastigmine in the treatment of Alzheimer’s disease: current and future directions
    Hamid Reza Amanatkar, George Thomas Grossberg · 2014 · Expert Review of Neurotherapeutics
  22. Combination Drug Therapy for the Treatment of Alzheimer’s Disease
    X. Anton Alvarez, Carlos Linares, Eliezer Masliah · 2012 · European Neurological Review
  23. The memory ameliorating effects of DHP1402, an herbal mixture, on cholinergic blockade-induced cognitive dysfunction in mice
    Haneul Kim, Hyung Eun Lee, In Ho Jung, Se Jin Jeon, Jiabao Zhang, Yubeen Kwon, Dae Sik Jang, Jong Hoon Ryu · 2017 · Journal of Ethnopharmacology
  24. Synthesis and Initial Characterization of a Reversible, Selective 18F-Labeled Radiotracer for Human Butyrylcholinesterase
    Christian Gentzsch, Xinyu Chen, Philipp Spatz, Urban Košak, Damijan Knez, Naoko Nose, Stanislav Gobec, Takahiro Higuchi, Michael W. Decker · 2021 · Molecular Imaging and Biology
  25. Binomial regression with a misclassified covariate and outcome
    Sheng Luo, Wenyaw Chan, Michelle A. Detry, Paul J. Massman, Rachelle Smith Doody · 2012 · Statistical Methods in Medical Research
  26. Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats
    Antonija Vukšić, Jasna Lovrić, Paško Konjevoda, Nina Blažević, Marinko Bilušić, Vlasta Bradamante · 2019 · Archives of Industrial Hygiene and Toxicology
  27. Pharmacological Treatment of Alzheimer’s Disease
    Lon S. Schneider · 2012 · Advances in biological psychiatry
  28. Pharmacogenomic Strategies in Alzheimer’s Disease: An In-Depth Review
    Yalan Zhou, Siqi Peng, Huizhen Wang, Xinyin Cai, Qingzhong Wang · 2024 · Journal of Medical Sciences and Interdisciplinary Research
  29. CDR State Transition Probabilities in Alzheimer's Disease with and without Cholinesterase Inhibitor Intervention in an Observational Cohort
    Lisa M. Bloudek, Eldon Spackman, David Leroy Veenstra, Sean D. Sullivan · 2011 · Journal of Alzheimer s Disease
  30. Pharmacological treatment for Alzheimer’s disease
    Kongkiat Kulkantrakorn · 2014 · Asian Medical Journal and Alternative Medicine
  31. Sorghum bicolor supplement attenuates rotenone-induced behavioral derangements in rats through neuroprotective mechanisms and modulation of tyrosine hydroxylase and α-synuclein/NF-kB immunopositive cells expressions
    Olajide S. Annafi, Paul Ademola Adeleke, Love Enebeli, Abayomi Mayowa Ajayi, Benneth Ben‐Azu, Olajuwon Okubena, Solomon Umukoro · 2025 · Journal of Molecular Histology
  32. Cohort Effects in Progression Rate on Cognitive and Functional Measures in an Alzheimer’s Disease Clinical Cohort
    Valory Pavlik, Wenyaw Chan, Eveleen J. Darby · 2019 · Journal of Alzheimer s Disease
  33. Persistence with anti-dementia medications: a systematic review and meta-analysis
    Mohammad Sistanizad, Gregory Mark Peterson, Tristan R. Ling, Mohammed Saji Salahudeen, Vyasamurthy Akondi, Woldesellassie M Mequanint Bezabhe · 2025 · Age and Ageing
  34. Pharmacogenomic Approaches in Alzheimer's Disease: A Comprehensive Review
    Ramdas Bhat, Varshini Varshini, Himasvi Himasvi, Ramakrishna Shabaraya · 2023 · International Journal of Pharmaceutical and Phytopharmacological Research
  35. Two Drugs Are Not Better Than One for Treating Moderate to Severe Alzheimer Disease, British Investigators Report
    Gina Shaw · 2012 · Neurology Today
  36. Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment
    Valory Pavlik, Rachelle Smith Doody · 2011 · Alzheimer s Research & Therapy
  37. Myeloid-mediated cerebral amyloid vasculitis and the potential role of the immune response in brain atrophy
    Rudy J. Castellani, Hinda Najem, Amy B. Heimberger, Pouya Jamshidi · 2025 · Journal of Clinical Investigation
  38. Improving Visual Working Memory with Cholinergic Deep Brain Stimulation
    Janki Bava, Zhengyang Wang, Sarah K. B. Bick, Dario J. Englot, Christos Constantinidis · 2023 · Brain Sciences
  39. S3-Leitlinien Demenzen
    Lucrezia Hausner, Lutz Frölich · 2013 · Nervenheilkunde
  40. P2‐048: Plasma sphingomyelin is associated with cognitive progression in Alzheimer's Disease
    Michelle M. Mielke, Norman J. Haughey, Veera Venkata Ratnam Bandaru, Danielle D. Weinberg, Noman Zaidi, Valory Pavlik, Rachelle Smith Doody, Constantine George Lyketsos · 2011 · Alzheimer s & Dementia
  41. Application status of memantine in patients with dementia in the Chongqing area of Southwest China
    Qi Tu, Yan Zou, Man Zhang, Ying Cao, Wenxiu Yang, Weihua Yu, Yang Lü · 2015 · Journal of Clinical Gerontology and Geriatrics
  42. Modeling the course of Alzheimer's disease to improve clinical trials: symposium report
    René Spiegel, Rachelle Smith Doody, Suzanne B. Hendrix, Kristin Kahle‐Wrobleski · 2013 · Alzheimer s Research & Therapy
  43. Neuroinflammation in Neurological Dysfunction and Degeneration
    Shih‐Heng Chen, Esteban A. Oyarzabal, Janine Hertzog Santos, Qingshan Wang, Lulu Jiang, Jau‐Shyong Hong · 2015 · Elsevier eBooks
  44. Estimation non paramétrique adaptative pour les chaînes de Markov et les chaînes de Markov cachées
    Claire Lacour A · 2007 · HAL
  45. Role of Artemisia macrocephala as enzymes inhibitor in dementia and nociception! A pharmacological study
    Ismail Shah · 2016 · Pure and Applied Biology
  46. Critical appraisal and role of memantine extended-release in the management of Alzheimer’s disease
    Indrapal Singh, George Thomas Grossberg · 2011 · Degenerative Neurological and Neuromuscular Disease
  47. Validation Prognostic of the Baylor Profound Mental Status Examination
    Sergio Salmerón Ríos, Silvia Lozoya-Moreno, Laura Plaza, Isabel Soler-Moratalla, Julián Solís, Pedro Abizanda · 2019 · Dementia and Geriatric Cognitive Disorders
  48. Old Age Dementias: Factors Associated with Dementia Progression Rate. Part 2
    N. M. Mikhaylova · 2020 · Psikhiatriya
  49. Anti-dementia Medication
    Vesna Jelić, Bengt G. Winblad · 2021 · Springer eBooks
  50. Russian experience in using a combination of fixed doses of donepezil and memantine in the treatment of Alzheimer’s disease as an observational non-interventional multicenter program
    Игорь Владимирович Колыхалов, Elen A. Mkhitaryan, Ya. B. Fedorova, Е. В. Пономарева, Наталья Дмитриевна Селезнева, M. A. Cherdak, Nadezhda G. Dudchenko, A B Seyfedinova, R. I. Isaev, Gavrilova Si et al. · 2023 · S S Korsakov Journal of Neurology and Psychiatry
  51. Neuroinflammation in Alzheimer's Disease Continuum
    Aslihan Taskiran Sag, Müge Yemişçi · 2020 · Neurological Sciences and Neurophysiology
  52. Assessment of In-House Natural Product and Synthetic Compound Libraries Based on In vitro Inhibition of Cholinesterases
    Päivi P. Järvinen · 2011 · Työväentutkimus Vuosikirja
  53. Capacités de jugement du danger et de raisonnement dans la démence de type Alzheimer
    Marion Boury, Mathilde Deschamps · 2013 · HAL
  54. P3‐038: Presence of cardiovascular disease is associated with slower cognitive decline in Alzheimer's disease in the absence of cerebrovascular pathology
    Mark Y. Chan, Valory Pavlik, Wenyaw Chan, Eveleen J. Darby, Aisha Khaleeq, Rachelle Smith Doody · 2010 · Alzheimer s & Dementia
  55. Establishment and validation of hippocampal LTP for characterization of memory enhancing drugs as potential treatment of Alzheimers disease
    Julius-Maximilians-Universität Würzburg · 2011
  56. From Curiosity to a Cure: The Role of Animal-Based Research In Treating Alzheimer's Disease
    Amber Young · 2010
  57. Imaging mouse models of neurodegeneration using multi-parametric MRI
    HE Holmes · 2015 · UCL Discovery (University College London)
  58. Risk Factors in Induction and Progression of Alzheimer’s Disease: Impacton Protection and Disease-Modifying Factors
    Azza A. Ali, Azza A. Ali · 2017 · Brain Disorders & Therapy
  59. Psychopharmacologic Agents to Enhance Cognition in Alzheimer’s Disease
    Alireza Atri, Theodore A. Stern · 2015 · Psychiatric Annals
  60. Kognitive Störungen
    Egemen Savaskan, Axel Wollmer, Jens Benninghoff · 2017 · Elsevier eBooks
  61. Neuropsychiatric Symptoms Are a Core Feature of Neurocognitive Disorders
    Maureen Cecilia Nash · 2019 · Springer eBooks
  62. Tolerability of antidementive therapy: results of observational research
    N. M. Zalutskaya, I. A. Beltceva, Nikolay G. Neznanov · 2018 · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
  63. Screening for Dementia: An examination of subscale relative importance
    Emily F. Matusz · 2018 · JMU Scholoraly Commons (James Madison University)
  64. Serum Ghrelin in Mild Cognitive Impairment and Alzheimer's Disease A Systematic Review and Meta-analysis
    Xiaodong Chen, Yunfeng Luo · 2021 · Research Square
  65. Cognitive Enhancers
    William James Deardorff, George Thomas Grossberg · 2018 · Springer eBooks
  66. Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage
    2017 · Elsevier eBooks
  67. Kognitive Störungen
    Egemen Savaskan, Axel Wollmer · 2020 · Elsevier eBooks
  68. Challenges of Combination Therapies in Alzheimer’s Disease
    Md. Sahab Uddin · 2020
  69. Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage
    2019 · Elsevier eBooks
  70. Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 10. Auflage
    2014 · Elsevier eBooks
  71. What predetermines the therapeutic tactics of a physician in the treatment of dementia? Results of a survey of Russian physicians
    N. A. Gomzyakova, A. V. Lukyanova, Н. Г. Незнанов, N. M. Zalutskaya · 2022 · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
  72. Phalsa (Grewia asiaticaL.)
    Manjeshwar Shrinath Baliga, Giriyapura Srikantachar Pavankumar, Karkala Sreedhara Ranganath Pai, Harish Kumar Bastimal, Beguvalli Subash Inchara, K. Pai · 2022 · CABI eBooks
  73. Ten principles of using the cholinesterase inhibitors in the treatment of dementia in clinical practice
    A D Chebotareva, Oleg Semenovich Levin · 2022 · Russian Medical Inquiry
  74. Literaturverzeichnis zu Voderholzer (Hrsg.): Therapie psychischer Erkrankungen, 20. Auflage
    2024 · Elsevier eBooks
  75. Patterns, determinants, and outcomes of early use of antidementia drugs: A 6-year multicenter cohort study in Thailand
    Sirayut Phatthanasobhon, Noppaket Singkham, Nat Na-Ek, Yuttana Wongsalap, Watchara Rattanachaisit, Yaowaret Mekkhayai, Kittipong Onseng, Roungtiva Muenpa, Pimsai Chindasu, Piyarat Winitkulchai et al. · 2024 · Archives of Gerontology and Geriatrics
  76. Clonidine attenuates chronic hypoxic stress-induced behavioral abnormalities in male Swiss mice through suppression of oxidative stress and pro-inflammatory cytokines
    Demilade Timothy Adebayo, Clinton Ijirigho, Paul Ademola Adeleke, Oladimeji E. Soremekun, Favour Boluwatife Jegede, Gbemisayo Adetomiwa Abbas, Lily Oghenevovwero Otomewo, Abayomi Mayowa Ajayi, Solomon Umukoro · 2025 · Naunyn-Schmiedeberg s Archives of Pharmacology
  77. Additional file 1 of Prevalence of treated patients with Alzheimer’s disease: current trends and COVID-19 impact
    Javier Olazarán, Cristóbal Carnero Pardo, Juan Fortea, Sánchez-Juan, Pascual, García-Ribas, Guillermo, Félix Viñuela, Martínez-Lage, Pablo, Merçé Boada · 2024 · Figshare
  78. Impact of dose and compliance of antidementia medications on long-term outcomes in Alzheimer’s disease: a nationwide real-world study
    Taewon Kim, Yun Jeong Hong, Mina Kim, Yoonjong Bae, Si Baek Lee, Seong Hoon Kim, Myung Ah Lee, Eunbuel Ko, Jeong‐Wook Park, Dong Won Yang · 2026 · Alzheimer s Research & Therapy
  79. Psychopharmacology and Neurocognitive Disorders: Evidence for Cognitive and Behavioral Symptom Management.
    Cody Olson, Marlene Maria Girón Bravo, G. González, M. E. Camp · 2026 · Focus
  80. New Insights into Drug Development and Immunotherapy for Alzheimer’s Disease
    Sakuntala Gayen, Souvik Roy, Md Alfaj Uddin, Dishani Sukul · 2026 · BENTHAM SCIENCE PUBLISHERS eBooks
  81. Nicotinic Acetylcholine Receptor Modulation Distinguishes Clinical Benefits of Galantamine in Alzheimer’s Disease
    Pavel Svintozelskiy, Andrew J. Wahlert, Carson Harrod, Denis George Kay, Kurt P. Grady, George Thomas Grossberg · 2026 · Sage Open Aging
  82. BindingDB Entry 50007047: Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model.
    BindingDB · 2021 · UC San Diego
  83. BindingDB Entry 50047319: Discovery of Highly Selective and Nanomolar Carbamate-Based Butyrylcholinesterase Inhibitors by Rational Investigation into Their Inhibition Mode.
    BindingDB · 2017 · UC San Diego
  84. BindingDB Entry 50043058: Investigation of the role of linker moieties in bifunctional tacrine hybrids.
    BindingDB · 2014 · UC San Diego